July 26, 2013
Study results support the use of biomarkers AFP-L3 and DCP for risk assessment in Surveillance
Researchers from Thomas Jefferson University Hospital, Philadelphia, PA, presented study results in a poster at the 2013 Digestive Diseases Week (DDW) Conference, supporting the use of serum biomarkers AFP, AFP-L3 and DCP for Risk Assessment in Surveillance of Patients at Risk for HCC development.
Clinical Diagnostic Reagents:
HCC Biomarkers and
Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of nearly 90 years of dedication to the field of in vitro diagnostics.
For Hepatocellular Carcinoma (HCC) Risk Assessment
Wako's AFP-L3 and DCP tests are available through major reference laboratories.
To learn how HCC biomarkers can improve surveillance of HCC: